Professor Jonathan Waxman trained at University College and University College Hospital, London, in common with a number of other consultants practising at LOC. He was the recipient of several scholarships and prizes as an undergraduate and postgraduate. He is currently Professor of Oncology at Imperial College London and consultant to the Department of Oncology at Hammersmith Hospital, for whom he played the central role in the campaign to build the Hammersmith Cancer Centre.

He founded the Prostate Cancer Charity which will raise £20m in this current financial year. Prior to joining the Hammersmith Hospital, he was an Imperial Cancer Research Fund Research Fellow at St Bartholomew’s Hospital.

His current clinical and laboratory research focus is prostate cancer. He has written over 400 research papers and book chapters, has authored eleven medical books, one novel, a patient information book and a legal text book. He writes on healthcare policy for major newspapers.

• Prostate
• Kidney
• Bladder
• Testicular cancers (chemotherapy)

• Prostate
• Kidney
• Bladder
• Testicular cancers (chemotherapy)

Professor Jonathan Ledermann is a Consultant Medical Oncologist, lead medical oncologist and the clinical research lead for gynaecological cancers in the North London Cancer Network, specialising in the treatment of gynaecological and colorectal cancers. His other research interests are in clinical trials and he is head of the UCL Cancer Trials Centre, one of the NCRI-accredited national cancer trials centres funded by research grants from Cancer Research UK. Professor Ledermann has developed and led several national and international trials in gynaecological cancer, currently leading two trials with novel drugs in ovarian cancer. 

Professor Ledermann graduated in medicine at UCL and UCH Medical School, subsequently training in medical oncology at UCH, Charing Cross Hospital London, and the Princess Margaret Hospital Toronto, before moving to UCL as a consultant in 1990. 

Professor Ledermann is a member of the NCRI clinical studies group for gynaecological cancers and one of the UK representatives on the GCIG (Gynaecological Cancer InterGroup). He has many publications to his name in the field of ovarian and colorectal cancer, serves on editorial boards for professional journals and is a medical advisor to several pharmaceutical companies. He is an acknowledged international expert in ovarian cancer and has lectured widely on his research.

• Treatment of gynaecological and colorectal cancers
• Ovarian cancer (chemotherapy)

• Gynaecological oncology
• Ovarian cancer (chemotherapy)
• Colorectal cancers

Dr Wilson is a Consultant Clinical Oncologist specialising in the treatment of thoracic malignancies (non-small cell lung cancer, small-cell lung cancer, mesothelioma, thymoma). He also offers radiotherapy for skin cancers (basal cell carcinoma, squamous cell carcinoma).

James Wilson completed his DPhil (PhD) at the University of Oxford in 2015, having been awarded a Cancer Research UK/Engineering and Physical Sciences Research Council fellowship. He finished his training at the Royal Marsden Hospital and was awarded a prestigious National Institute for Health Research Clinical Lectureship position at The Institute of Cancer Research in 2016. He is a member of the Royal College of Physicians and fellow of the Royal College of Radiologists.

He is a core member of the oligometastatic multi-disciplinary team (MDT) and offers stereotactic radiotherapy for primary and secondary lung cancers and metastases to the spine, bone and other sites. He represents clinical oncology at the specialist spinal tumour MDT at the National Hospital for Neurology and Neurosurgery.

Dr Wilson has worked in London's leading cancer centres. He is a Consultant Clinical Oncologist at University College London Hospital. As an Associate Professor at UCL he is leading research to improve treatment outcomes for patients. Dr Wilson is a specialist committee member for NICE (National Institute for Health and Care Excellence).

Diseases, Medical Tests and Treatments

• Thymoma
• Thymic carcinoma
• Non-small cell lung cancer
• Small cell lung cancer

Dr Rassam Qualified in 1980 from the University of Baghdad. In 1986 he arrived to the UK on a scholarship for post-graduate training in haematology. He trained as a Registrar at the Royal Free Hospital, London and Edgware General Hospital and a Senior Registrar and University of London Lecturer at St Bartholomew’s Hospital, University College Hospital and Hospital for Sick Children at Great Ormond Street. During his time as a senior registrar, he conducted research into immune reconstitution following stem cell transplantation in children with severe combined immune deficiency. He received his Membership of the Royal College of Physicians and the Royal College of Pathologists in 1989 and 1992 respectively and was elected as Fellow of both colleges in 1997 and 1999.

Dr Rassam has a special interest in the management of lymphoid malignancies and in research into the immune mechanisms and therapy of cancer. In 1997 he was awarded The Microscopical Society of Great Britain and Ireland Fellowship to study the technology and isolation of tumour infiltrating lymphocytes (the immune cells against cancer) at Harvard University in the USA. Following his return, he established a research laboratory at Queen Mary’s Hospital to study the role of the immune system in lymphatic cancer and has presented his findings in National and International meetings. Dr. Rassam has continued in his efforts in the world of research as has won a number of prestigious awards.

Dr. Rassam is an active member of the low and high grade lymphoma subgroups of the National Cancer Research Institute (NCRI), the British Society of Haematology, the American Society of Haematology, The UK Waldenstroms Macroglobulinaemia Group and an author on the British Society of Haematology Guidelines in Waldenstrom’s Macroglobulinaemia. He is an examiner and appointment advisory officer for the Royal College of Pathologists. He is the author of a number of National clinical trial proposals. He is also the chairman of the Hemato-Oncology Group in the Kent Cancer Network and responsible for updating the lymphoma and chronic lymphocytic leukaemia (CLL) pathways. He is the National Chief Investigator for the ASCEND study in CLL.

Diseases, Medical Tests and Treatments

• Chemotherapy
• General Haematology
• Haematological oncology
• Lymphoma: Hodgkin and non-Hodgkin
• Myeloma
• Leukaemia

Dr Karavasilis is part of the sarcoma team at UCLH, specialising in the systemic treatment of adult patients with various types of sarcomas, including bone sarcomas and GISTs. He is also Assistant Professor of Oncology at Aristotle University of Thessaloniki, Greece and was previously their director of the Medical Oncology.

Dr Karavasilis has a strong interest in clinical and translational research in sarcomas, particularly looking for novel agents for the treatment of this type of cancer. He also has over 15 years’ experience in clinical trials.

• Chemotherapy

• Sarcoma
• Soft Tissue Sarcoma

www.harleystreet-cancer-expert.com

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Dr Jeremy Steele received his medical education at the University of London St George's Hospital Medical School. He proceeded to the Royal Marsden Hospital to train in cancer medicine after first training in acute general medical specialties and intensive care medicine. During this time, he conducted studies on lung cancer, brain tumours, and childhood leukaemia and received his Doctor of Medicine degree for his work on cancer biology. He then undertook oncology training at St. Bartholomew's Hospital and the Royal London Hospital in London's East End. In 1999, he became a visiting fellow at Harvard Medical School's thoracic oncology centre in Boston.

Dr Steele also led one of the first effective clinical studies of mesothelioma therapy in East London, the centre of the city's malignant mesothelioma epidemic. He joined Barts in 2002 as a consultant oncologist with a special interest in lung cancer and mesothelioma.

Dr Steele is renowned in the UK as a lung cancer specialist, and he is globally recognised as an expert in the diagnosis and treatment of malignant mesothelioma. He is the secretary of the International Mesothelioma Group (iMig), located in Chicago, and the chairman of the Mesothelioma UK Charitable Trust's advisory board. He also has a lengthy history of patient advocacy and has successfully lobbied the UK Government for the availability of novel cancer medicines.

Diseases, Medical Tests and Treatments

• Malignant mesothelioma (pleural and peritoneal)
• Immunotherapy for mesothelioma and lung cancer
• Maximisation of quality of life
• Patient-centred cancer care
• Malignant mesothelioma (pleural and peritoneal)
• Immunotherapy for mesothelioma and lung cancer
• Maximisation of quality of life
• Patient-centred cancer care

Dr Carmel Coulter is a Consultant Oncologist based in London, UK. Following her graduation from The Royal Free Hospital School of Medicine she undertook specialist cancer medicine training at St Bartholomew’s Hospital. Following this, she was appointed as the Consultant Clinical Oncologist at St Mary's and The Middlesex Hospitals.

She has a specialist interest in the treatment of breast and gynaecological cancer patients and has extensive experience using both chemotherapy and radiotherapy techniques.

 Dr Coulter is dedicated to providing the best possible cancer treatment combined with the best possible overall holistic care of the patient.

Dr Danielle Power is a Consultant Clinical Oncologist, based at Imperial College NHS Trust and Honorary Senior Lecturer at Imperial College. She specialises in gastrointestinal cancers, lung, upper gastrointestinal cancers, small cell lung cancer, non small cell lung and other types of lung cancer. She undertook oncology training in London at a range of specialist centres, including the Royal Marsden Hospital, Mount Vernon Cancer Centre, University College Hospital and Hammersmith Hospital.

Dr Power has been awarded a Fellowship of the Royal College of Radiologists. She was also appointed a Consultant and Honorary Senior Lecturer at St Mary’s Hospital and subsequently at Imperial College Healthcare NHS Trust, with specialist interest in oeosphagogastric cancer, lung cancer and thyroid malignancies. She is trained in chemotherapy, immunotherapies, biological therapies and radiotherapy. Including stereotactic radiotherapy and the use of radionuclide therapies. She is also active in teaching, training and is an investigator or co-investigator in a number of clinical trials. In 2017, Dr Power was appointed Clinical Director for Oncology & Palliative Care Services at Imperial College Healthcare NHS Trust.

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Biological Therapy
• Palliative Care

• Oesophageal Cancer
• Thyroid Cancer
• Lung Cancer

Dr Stephen Harland was appointed Senior Lecturer in Medical Oncology at the Institute of Urology in 1986. Since then, he has specialised in testis, bladder and prostate cancers and has led on the medical oncological treatment of these tumours at Middlesex and University College Hospitals.

Dr Harland has been active in research into urological cancer throughout his consultant career and his publications reflect this. He has served as Chairman of the MRC Bladder Cancer Group, of the North London Urology Tumour Board and the Castration-resistant Subgroup of the National Cancer Research Network Prostate Cancer Clinical Studies Group. He was on the Editorial Committee of the Government's document for improving outcomes in urological cancer and has been a frequent speaker at international meetings.

Recent appointments have been at the Royal Marsden Hospital, St George’s Hospital and the Royal Surrey County Hospitals.

• Prostate cancer
• Bladder cancer
• Testicular cancers (chemotherapy)

• Prostate cancer
• Bladder cancer
• Testicular cancers (chemotherapy)